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Abstract
Aims: To investigate whether combinations of routinely available clinical features can
predict which patients are likely to be non-adherent to diabetes medication.
Materials and Methods: A total of 67 882 patients with prescription records for their
first and second oral glucose-lowering therapies were identified from electronic
healthcare records (Clinical Practice Research Datalink). Non-adherence was defined
as a medical possession ratio (MPR) ≤80%. Potential predictors were examined,
including age at diagnosis, sex, body mass index, duration of diabetes, glycated
haemoglobin, Charlson index and other recent prescriptions.
Results: Routine clinical features were poor at predicting non-adherence to the first
diabetes therapy (c-statistic = 0.601 for all in combined model). Non-adherence to
the second drug was better predicted for all combined factors (c-statistic =0.715) but
this improvement was predominantly a result of including adherence to the first drug
(c-statistic =0.695 for this alone). Patients with an MPR ≤80% for their first drug
were 3.6 times (95% confidence interval 3.3,3.8) more likely to be non-adherent to
their second drug (32% vs. 9%).
Conclusions: Although certain clinical features were associated with poor adherence,
their performance for predicting who is likely to be non-adherent, even when com-
bined, was weak. The strongest predictor of adherence to second-line therapy was
adherence to the first therapy. Examining previous prescription records could offer a
practical way for clinicians to identify potentially non-adherent patients and is an
area warranting further research.
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1 | INTRODUCTION
Adherence to oral glucose-lowering therapies is a major problem in
diabetes, with up to two-thirds of patients not taking their medication
as prescribed.1,2 Poor medication adherence is associated with poor
glycaemic response, with patients who take <80% of their intended
medication achieving half the expected reduction in glycated
haemoglobin (HbA1c).3
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Identifying which patients are likely to be non-adherent would
have clear benefits in enabling interventions aimed at improving medi-
cation adherence, and consequently, improving glycaemic control. A
wide range of factors have been shown to be associated with poor
adherence to diabetes medications including clinical features (female
sex, younger age, non-white ethnicity), other comorbidities such as
depression,2 the class of medication and other prescriptions (medica-
tions after first-line metformin,4 total daily pill burden),5,6 healthcare
system (insurance, medication costs)2,5 and psychosocial factors (med-
ication beliefs, physician trust).6,7 In addition, adherence to previous
medications has been shown to help improve predictive ability for
determining adherence to statins8,9 and, more recently, in patients
with cardiometabolic disorders.10 Adherence differs by medication
class, with adherence being poorer with first-line metformin therapy.4
The time of first intensification, is therefore an appropriate time point
to review adherence when considering optimal second-line treatment.
In order to develop a practical clinical tool for identifying patients
likely to be non-adherence, it needs to be based on routinely available
clinical features. Combinations of features are likely to yield greater
predictive ability, but they need to be combined appropriately. Clinical
prediction models, such as Q-Risk or the Framingham risk score, pro-
vide a way of including multiple clinical predictors to determine the
probability or risk of a particular outcome, and the utility of these can
be increased by embedding them into routine clinical systems.
We aimed to determine whether clinical features and prescription
records in routine primary care data could be combined in a clinical
prediction model to help identify patients most likely to be non-
adherent to type 2 diabetes medications.
2 | METHODS
2.1 | Study cohort
Data were extracted on all patients starting oral glucose-lowering
drugs after January 1, 2004 registered with general practitioners
(GPs) contributing to the Clinical Practice Research Datalink (CPRD).
The CPRD is the largest validated primary care longitudinal health
record database in the world, with data from >700 general practices
throughout the UK. The dataset comprised the General Practice
Online Data (CPRD GOLD), downloaded in January 2018. We did not
extract data from patients treated with injectable therapies or oral
solutions as either their first- or second-line diabetes treatment.
A detailed explanation of our data cleaning and inclusion criteria
has been published previously, including code lists.3 In brief, to ensure
only patients with Type 2 diabetes were included, patients who had
either no record of diabetes, polycystic ovary syndrome treated with
metformin, or other forms of diabetes (eg, maturity-onset diabetes of
the young, steroid-induced) were excluded using standard CPRD
medcodes.3 As there are known coding errors with Type 1 diabetes in
primary care,11 patients with likely type 1 diabetes were removed
from the data by excluding patients with an age at diagnosis <35 years
or those prescribed insulin within 1 year of diagnosis.
Patients were included in the analysis where at least 1 year of pre-
scribing data were available and there were no gaps in registration.
We removed records where patients started two drugs at the same
time (2.2% of records). For patients whose first prescriptions were
within 91 days of the current registration date we had no way of
determining whether these were genuine new diabetes cases or
whether they were continuing existing therapy, as we had no details
of their previous practice records. These cases were therefore
excluded.
As the focus of our analysis was on the first intensification of dia-
betes therapy, patients who only had records for their first-line diabe-
tes therapy but no subsequent therapies were excluded.
2.2 | Calculating adherence
Adherence to the first- and second-line therapies was determined by
GP issue of prescriptions for glucose-lowering medication. The medi-
cal possession ratio (MPR) was used as the metric by which to report
adherence.12 MPR was defined as the number of days of available
medication (calculated by dividing the quantity prescribed by the daily
dose for each prescription) divided by the number of days between
the first prescription and the adherence period end date, multiplied by
100. The adherence period end date was defined as (i) 365 days after
the first prescription date (if the patient remained on the same diabe-
tes treatment within that time period), or (ii) for patients who
stopped/changed drug within a year or the prescription records ended
within a year, the penultimate prescription date before the stop or
change (as subsequent prescriptions are needed to determine days
covered between prescriptions). In line with previous work, for MPR
to be calculated, the patient needed to have at least three valid pre-
scriptions for the drug covering at least 90 days, and not have a break
between prescriptions of >6 months (as this was considered “stop-
ping” the drug). In some instances (21% of 6 589 177 prescription
records in the CPRD), the daily dose was recorded as zero. Where
dose information was not available for any of the prescriptions within
the adherence period, MPR was not calculated. For those where there
were at least three valid prescriptions, but dose was missing from
others, we removed the prescription with missing dose and the time
between that prescription and the next from the denominator. An
MPR <20% or > 120% was considered to reflect errors in recording of
dose and so was excluded.
2.3 | Predictors
Age at diagnosis was defined as described previously based on the
age at the earliest of diabetes drug code, HbA1c in diabetes range, or
prescription for glucose-lowering medication.3 Baseline BMI and
HbA1c are reported as the closest to the drug start date within the
previous 6 months. To determine use of other non-diabetes medica-
tions at baseline, prescriptions were extracted for patients for the
3 months prior to the drug start date. Mean number of tablets per day
was calculated based on the total quantity of tablets for available pre-
scriptions in that time period divided by 91 (quantity was chosen
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rather than daily dose as this was recorded more frequently). Blood
pressure- and lipid-lowering treatments were identified based on Brit-
ish National Formulary codes. The Charlson comorbidity index was
calculated to determine the impact of comorbidities using previously
published codes.13 MPR for the first drug was used as a predictor of
MPR for the second drug.
2.4 | Statistics
2.4.1 | Defining non-adherence
Clinically, the most important question is how likely patients are to be
non-adherent rather than accurately trying to predict the actual adher-
ence, particularly as the majority of patients have high adherence levels.
Furthermore, the association between adherence to the first- and
second-line drugs was non-linear, and initial simple models treating
adherence as a continuous outcome showed poor model fit. We chose
to focus on logistic regression modelling, therefore, comparing those
with ≤80% MPR with those with >80%MPR. MPR≤80% was chosen to
reflect non-adherence as it is the most commonly used indicator2 and is
the threshold below which poor adherence impacts on response.3
2.4.2 | Model development
Models to predict non-adherence to therapy (MPR≤80%) were built
using logistic regression. Changes to coefficients and model fit were
checked at each stage to ensure models were robust. The shapes of
the associations with the model outcome were checked by general-
ized additive model plots of the fits of each of the continuous predic-
tors against the binary adherence outcome. For non-linear
associations, simple linear splines were used in regression models with
knots defined at turning points seen on the plots and coefficients for
the separate slopes extracted to aid interpretation of results. Adher-
ence to the first drug was added as a predictor of non-adherence to
the second drug as a binary variable split at 80% MPR and was also
treated continuously in logistic regression models. When analysed
continuously MPR was capped at 100% as the association with model
outcome flattened out after this point. As a final sensitivity analysis,
restricted cubic splines were used for all continuous variables in full
multivariable models to determine whether the fit of the models could
be improved further.
Models were developed on a complete case basis. No imputation
was carried out, but variables were in general available on >80% of
the cohort, and models were checked for their sensitivity to missing
data. Ethnicity was poorly captured, comprising only 48% of the
patients, so separate models were developed including and excluding
ethnicity.
Performance of the models was determined using receiver-
operating characteristic (ROC) curve analysis, the c-statistic (equiva-
lent to area under the ROC curve of the predicted probabilities from
the logistic regression models), Somers' rank correlation (Dxy), and
Nagelkerke's R2.
Coding of the CPRD data was carried out in STATA version 14. Sta-
tistical analysis was carried out in R version 3.5.1.
2.5 | Ethics
Approval for the study was granted by the CPRD Independent Scien-
tific Advisory Committee (ISAC protocol 18_062).
3 | RESULTS
A total of 198 628 patients with Type 2 diabetes had prescription
records for oral glucose-lowering drugs since 2004. Following removal
of those records with too little or incomplete data there were
129 565 patients with sufficient quality data. A total of 67 882
patients had prescription records for both their first- and second-line
therapies and so were eligible for analysis. The 61 683 patients who
only had prescription records for a first-line therapy had a shorter
period of prescriptions covered (mean 4.3 years vs. 6.7 years) and
were less likely to be metformin-treated (88% vs. 93%) than those
who also had records for a second drug.
Figure 1 shows the coding of the 67 882 patients suitable for
analysis. Of these, 24 400 (36%) had a valid adherence measure on
both their first and second diabetes medication (characteristics in
Table S1). The characteristics of patients for whom adherence could
be calculated were broadly similar to those with missing data and
those who stopped/changed their treatment within 90 days (Tables S2
and S3), except missing dose data were more likely in those whose
second drug was a sulphonylurea, and patients who stopped/changed
their first treatment were less likely to be treated with metformin and
had a higher HbA1c level.
3.1 | Adherence to first diabetes therapy: Clinical
predictors explain little variance in adherence
3.1.1 | Pill burden as a predictor of non-adherence
In all, 19% of the cohort had an MPR ≤80% for their first drug.
Patients who were non-adherent to their first drug (MPR≤80%) were
more likely to have a lower HbA1c, to be treated with fewer tablets
per day at baseline, to have a longer diabetes duration and to be
younger, and were less likely to be treated with lipid-lowering treat-
ment, anti-hypertensive treatment and anti-depressive treatment (-
Table S4). Those treated with metformin were more likely to be non-
adherent (MPR≤80%) than those treated with other tablets (21%
vs. 11%; P < .0001).
3.1.2 | Clinical and demographic characteristics of
non-adherence
In logistic regressiong models (Tables S4 [univariate] and Table S5 [mul-
tivariable]), younger age at diagnosis was associated with a decreased
probability of being non-adherent, but only up to the age of 70 years
(Figure S1). Treatment with blood pressure-lowering drugs was
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associated with being non-adherent, but this association disappeared
when adjusting for number of tablets per day. Coefficients for all other
predictors remained similar when added into a combined multivariable
logistic regression model (Table S5). Although highly significant given
the large sample size, associations were weak, even with all predictions
combined (Nagelkerke's R2 = 0.033), and the full multivariable model
showed a weak correlation between predicted probabilities and out-
come (Dxy = 0.2). The ROC curve of predicted values from the full
logistic regression model showed poor discrimination between adherent
and non-adherent patients (c-statistic =0.601; Figure 2).
3.2 | Adherence to the first drug was the major
predictor of adherence to the second drug
3.2.1 | Pill burden as a predictor of non-adherence
Adherence to the second diabetes drug was higher than adherence to
the first drug (95.5% vs. 92.5%; P < .0001), with fewer patients having
an MPR≤80% for their second drug (14% vs. 19%; P < .0001). Those
treated with metformin were more likely to be non-adherent
(MPR≤80%) compared with those treated with other drugs (17%
vs. 13%; P < .0001). The differences in characteristics between adher-
ent and non-adherent patients for their second drug are shown in
Table S6. In univariate analysis, the strongest predictor of being non-
adherent to the second drug was the MPR for the first drug (z = 37.5,
Table S6). A total of 32% of those with an MPR≤80% on their first
drug were non-adherent on their second drug compared with only 9%
with an MPR > 80% (relative risk 3.6 [95% confidence interval 3.3,
3.8]). Those with the lowest rates of adherence to their first drug were
the most likely to be non-adherent to their second drug (Figure 3).
Adherence to drug 1, as either a binary (≤80% or > 80% MPR) or con-
tinuous predictor of adherence to the second drug had better discrim-
inative ability than all clinical features combined for the first drug
(c-statistic =0.646 [binary] and 0.695 [continuous] vs. 0.601 [clinical
features only]; Figure 4A).
3.2.2 | Clinical and demographic characteristics of
non-adherence
In terms of other predictors (Tables S6 [univariate] and Table S7 [mul-
tivariate]), greater number of tablets per day was associated with
lower probability of being non-adherent, with the association flatten-
ing out after 10 tablets (Figure S1). Patients who were non-adherent
were less likely to be treated with blood pressure- and lipid-lowering
treatment, but the associations weakened when added into logistic
regression models with other features, and became non-significant
when adding in mean number of tablets per day. Use of anti-
depressant medication was associated with being non-adherent, and
this association became stronger when adding in mean number of tab-
lets per day.
The level of HbA1c and duration of diabetes showed weak associ-
ations with adherence to second therapy, with higher HbA1c and
shorter duration associated with being more likely to be non-adher-
ent. Similarly to the association with first diabetes therapy, younger
age showed a weak association with being non-adherent up until age
70 years, after which the association flattened out (Figure S1). Other
F IGURE 1 Coding of adherence
category for the 67 882 patients eligible
for analysis. DPP-4, dipeptidyl peptidase-
4 inhibitors; MFN, metformin; MPR,
medical possession ratio; SU,
sulphonylureas; TZD, thiazolidinediones
F IGURE 2 Receiver-operating characteristic curve showing the
discrimination between adherent and non-adherent patients for the
first diabetes drug when using predicted values from the full logistic
regression model (c-statistic =0.601)
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factors including gender, body mass index and Charlson comorbidity
index were not associated with adherence.
The addition of all other features in the model added little in terms
of prediction and discriminative ability between adherent and non-
adherent patients over and above using adherence to the first drug
alone (adherence explained 80% of the log likelihood of the full model;
c-statistic =0.716 [combined model] vs. 0.695 [adherence alone]). A
full model where restricted cubic splines were fitted for all continuous
variables resulted in significantly better fit (likelihood ratio χ2 = 86.9,
P < .00001); however, this resulted in marginal improvement in dis-
criminative ability between adherent and non-adherent patients (c-
statistic =0.721), despite the increase in complexity.
When ethnicity was added to the models (Tables S8 and S9)
patients of black and Asian ethnicity were found to be more likely to
be non-adherent compared with patients of white ethnicity. Coeffi-
cients remained broadly similar, and changes mainly reflected the
smaller dataset rather than the addition of ethnicity to the model. Eth-
nicity significantly added to the full logistic regression model
(likelihood ratio χ2 = 33, P < .0001 when compared with full model on
only those with ethnicity recorded); however, the improvement in dis-
crimination between adherent and non-adherent patients was mar-
ginal (0.724 vs. 0.719 when models developed on datasets of only
those with ethnicity recorded).
4 | DISCUSSION
We found that the strongest predictor of being adherent to second-
line therapy in type 2 diabetes was a patient's adherence to their first-
line therapy. Our findings show that patients with ≤80% adherence to
their first drug were nearly four times more likely to be non-adherent
to their second drug, and the risk of non-adherence on the second
drug increases as the MPR for the first drug decreases. Other rou-
tinely available clinical features, although statistically significant, offer
little additional discriminative ability in identifying likely non-adherent
patients; therefore, although there are many clinical features that are
associated with non-adherence to medications as has been previously
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reported, most are not sufficiently predictive for clinical discrimination
even when used in combination, and the only indicator with reason-
able discriminative ability is recording of prescribing of medication.
This is likely to relate to the fact that many predictors of adherence
are social or psychological and therefore not captured by routine data.
Previous studies have identified a wide range of factors that were
associated with low adherence.2,5-7 Some of these relate to the con-
text in which adherence is being examined. For example, one study
examining a pharmacy claims database in a healthcare system where
co-payments by patients are required reported factors such as income
and out-of-pocket costs as relevant.5 Other studies cite associations
but do not report the extent to which these contribute to overall
non-adherence.2 As noted in a recent review, many of the factors
identified as having an association with medication adherence are
inconsistent across studies and are not modifiable.6 More recent stud-
ies have started to examine the relative contribution of different risk
factors for non-adherence across a range of treatments for long-term
conditions: prior non-adherence and trajectories of use of treatment
appear to be consistent and clinically relevant factors.8-10
There are two factors widely cited in the literature that are of par-
ticular note: depression and ethnicity. A systematic review and meta-
analysis has shown an association of depression and non-adherence
with diabetes treatment recommendations including medication
use14; however, measurement of adherence, particularly with self-
report can be biased for some types of measure.15 The extent to
which depression leads to non-adherence, or whether non-adherence
to a wide range of self-care activities leads to depression is unclear.16
Non-white ethnicity is another key factor associated with non-
adherence,17 but the issues associated with this are complex.7
Although both of these factors were identified as significantly associ-
ated, they added little in terms of further discrimination in the full
models. It is possible with the limited data we had that we may have
underestimated their effects in our population, and in some settings
these factors may be important discriminators.
Many factors relating to non-adherence to diabetes medications
are not captured in routine data. Nevertheless, it is possible that pat-
terns of previous prescriptions issued could provide a practical indica-
tor that clinicians could use to determine those where further
assistance may be offered to improve adherence. Looking at dates
when previous medications were prescribed and determining whether
they are consistent with regular usage may offer a simple indicator,
particularly if previous prescription coverage was considerably longer
than that implied by the prescribed dose.
With the evidence provided by these data, along with other recent
studies, there are now strong indications that monitoring of adher-
ence could be of benefit. Although GP computer systems have the rel-
evant data available and some can calculate previous MPRs based on
prescription dates and prescribed daily dose, algorithms to improve
data quality such as range and error checks are not in place and would
be an important area for future consideration. With increasing avail-
ability of digital data, different sources of data could be incorporated
to improve the accuracy with which individuals at risk might be identi-
fied, including dispensing data and home monitoring (including diaries)
of taking medications. There is also a need to monitor constantly the
clinical pathways through which the prescribing and dispensing of
medications occur, for example, the automatic prescribing of prescrip-
tions at regular intervals does not necessarily lead to the dispensing or
collection of those medications by a patient. Prompts for medication
collection by online pharmacies are already available to many patients,
but linkage of data with other parts of the healthcare system is
needed. Making this available to patients to inform their own
decision-making, potentially with targeted and tailored messaging
around best use of medication, is an area currently being
explored.18,19
Major strengths of the present study include the large sample size
and use of real-life data, so reflecting what is currently happening in
routine primary care. This meant that we were able to study simple
clinical features easily available in clinical practice. By combining mea-
sures in prediction models, we have been able to move beyond simple
associations to instead determine which factors are sufficiently useful
to help identify potential non-adherent patients.
The present study has a number of limitations. Routinely collected
electronic health record observational data are messy and some fields
are poorly captured. In particular, ~20% of prescribed doses were
missing in the dataset. Furthermore, we used MPR as our outcome
measure of adherence, but this is only related to prescriptions issued
rather than those collected. However, it is a widely accepted measure
and, although likely to underestimate overall adherence measures,
offers a practical way of exploring non-adherence in routine data. The
main models presented were based on logistic regression predicting
non-adherence defined based on an MPR≤80% compared with an
MPR > 80% and so some information may have been lost due to
dichotomization. We chose to use this outcome as it is a commonly
used indicator for non-adherence and is the threshold below which
poor adherence impacts on glycaemic response to therapy. As a sensi-
tivity analysis, we tried more complex modelling methods and none of
the approaches resulted in significant gains in predictive ability, partic-
ularly given their added complexity and the difficulty in interpreting
findings. We therefore see the present paper as highlighting the
importance of adherence to previous medications compared with
other baseline factors, rather than producing a final prediction model
for non-adherence, which would be important to build upon in future
work. The extent to which prediction might vary between medications
and across different conditions remains to be explored further.
In conclusion, we have shown that the strongest predictor of adher-
ence to second-line therapy in type 2 diabetes is previous adherence to
the first-line therapy. Examining previous prescription records would
offer a practical way for clinicians to identify potentially non-adherent
patients and is an area warranting further research.
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